<DOC>
	<DOCNO>NCT00789373</DOCNO>
	<brief_summary>This study compare progression-free survival patient advance non-squamous non-small cell lung cancer . Patients progress follow 4 cycle induction treatment pemetrexed cisplatin randomize 2:1 receive either maintenance pemetrexed placebo .</brief_summary>
	<brief_title>A Study Induction Maintenance Treatment Advanced Non-squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Inclusion Criteria Induction Phase : You must sign informed consent document clinical research . You must Stage IIIB IV nonsquamous NonSmall Cell Lung Cancer . You must least able physically mobile , take care , must able perform light activity light housework office work . You allow prior radiation therapy long 25 % bone marrow include whole pelvis . Thoracic radiation must complete 30 day study . You must recover toxic effect ( except hair loss ) . You must least 1 measurable tumor lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) guideline disease evaluate computed tomography ( CT ) Scan . Your test result assess function blood form tissue , kidney , liver must satisfactory . You must 18 year age old . Women must sterile , postmenopausal contraception men must contraception sterile ( e.g . postvasectomy ) . Exclusion Criteria Induction Phase : You squamous cell and/or mixed small cell , nonsmall cell lung cancer You receive investigational drug within last 30 day enter trial . You previously complete withdrawn study study investigate pemetrexed . You serious ongoing illness include active infection . You serious cardiac condition , heart attack , angina , heart disease within 6 month enter trial . You another form cancer superficial basal cell superficial squamous ( skin ) cell cancer , carcinoma situ cervix within last 5 year . Patients history lowgrade ( Gleason score less equal 6 ) localize prostate cancer eligible even diagnose less 5 year ago . You known central nervous system ( CNS ) metastases , treat , stable brain metastasis . You receive receive prior systemic anticancer therapy lung cancer ( include chemotherapy give surgery earlystage treatment ) . You clinically significant thirdspace fluid collection ( e.g . ascites pleural effusion control drainage procedure ) . You receive recent ( within 30 day ) receive yellow fever vaccination . You unable stop take 1.3 gram aspirin daily basis nonsteroidal antiinflammatory drug ( NSAIDs ) . You unable unwilling take folic acid , injection vitamin B12 , corticosteroid . You pregnant breastfeed . Inclusion criterion Randomization Maintenance Phase : You must least able physically mobile , take care , must able perform light activity light housework office work . You must document radiographic evidence tumor response complete response ( CR ) , partial response ( PR ) , stable disease ( SD ) accord Response Evaluation Criteria Solid Tumors ( RECIST ) guideline . Tumor assessment must occur Cycle 4 ( Day 1 ) induction therapy date randomization . This response confirm order patient randomize maintenance phase .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>